ChartMill assigns a Buy % Consensus number of 87% to MBX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-19 | Stifel | Maintains | Buy -> Buy |
| 2025-12-04 | Goldman Sachs | Initiate | Sell |
| 2025-11-10 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-04 | TD Cowen | Initiate | Buy |
| 2025-10-15 | Truist Securities | Initiate | Buy |
| 2025-09-24 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-09-23 | Guggenheim | Maintains | Buy -> Buy |
| 2025-09-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-08-05 | Mizuho | Initiate | Outperform |
| 2025-07-16 | Oppenheimer | Initiate | Outperform |
| 2025-04-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-04-10 | JMP Securities | Initiate | Market Outperform |
| 2024-10-08 | Guggenheim | Initiate | Buy |
| 2024-10-08 | Stifel | Initiate | Buy |
| 2024-10-08 | JP Morgan | Initiate | Overweight |
| 2024-10-08 | Jefferies | Initiate | Buy |
12 analysts have analysed MBX and the average price target is 60.44 USD. This implies a price increase of 95.58% is expected in the next year compared to the current price of 30.9.
The consensus rating for MBX BIOSCIENCES INC (MBX) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.